Recent developments highlight narrowing net losses, FDA alignment for pivotal Phase 3 trial, and plans for study initiation in mid-2027.

• Cognition Therapeutics reported a narrowed net loss in Q2 2026 and announced plans to initiate a Phase 3 study of Zervimesine in Dementia with Lewy Bodies in mid-2027 [N1].
• The company reported a Q2 2026 net loss and noted revenue lagging estimates [N2].
• FDA alignment was secured for the pivotal Phase 3 trial of Zervimesine in DLB psychosis as of June 2026 [N3].
• The company completed a Type C meeting with the FDA regarding Zervimesine in Dementia with Lewy Bodies in January 2026 [N5].
• Q2 2026 financial results showed a net loss of $3.932 million and EPS of -$0.04, with strong liquidity including $34.012 million in cash and equivalents as of June 30, 2026 [S2].

The company has demonstrated progress in clinical development with FDA alignment for a pivotal Phase 3 trial of Zervimesine in Dementia with Lewy Bodies psychosis. Positive Phase 2 results and narrowing net losses indicate advancing clinical and financial management. Strong liquidity supports ongoing operations and trial preparations. Continued regulatory progress and successful trial execution could enhance the company's position in neurodegenerative disease therapeutics.

Risks include the inherent uncertainties of clinical trial outcomes, regulatory approval processes, and the need for additional capital to fund operations. The company operates at a net loss and depends heavily on the success of its lead candidate, Zervimesine. Competition from other therapies and potential delays or failures in clinical development could adversely impact the company’s prospects. Market and operational risks typical of clinical-stage biopharmaceutical companies apply.

Cognition Therapeutics' moat is based on its novel approach targeting the sigma-2 receptor complex, a relatively new therapeutic pathway for neurodegenerative diseases. The company’s lead candidate, Zervimesine, has advanced clinical data and regulatory engagement, which may provide competitive differentiation. However, the biotech sector's inherent risks, including clinical trial outcomes and regulatory approvals, limit the moat's strength until product commercialization.

• Clinical Development Risk: The success of Zervimesine depends on positive outcomes from ongoing and future clinical trials, which are inherently uncertain.
• Regulatory Risk: Obtaining and maintaining regulatory approvals for clinical trials and eventual marketing authorization involves significant uncertainty and potential delays.
• Financial Risk: The company currently operates at a net loss and requires additional capital to fund its operations and clinical development programs.
• Dependence on Lead Product Candidate: The company’s business is highly dependent on the success of Zervimesine; failure of this candidate would materially impact the company.
• Competition Risk: Competing therapies in neurodegenerative diseases may limit market opportunities and affect the company’s commercial potential.

• Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, particularly targeting the sigma-2 receptor complex.
• The company's lead product candidate is Zervimesine (CT1812), which is being developed for Alzheimer's disease and Dementia with Lewy Bodies (DLB).
• The company has completed a Type C meeting with the FDA regarding Zervimesine in Dementia with Lewy Bodies, indicating regulatory engagement for clinical development [N5][S1].
• Cognition Therapeutics has secured FDA alignment for a pivotal Phase 3 trial of Zervimesine in DLB psychosis [N3].
• The company plans to initiate a Phase 3 study of Zervimesine in Dementia with Lewy Bodies in mid-2027 [N1].
• Recent Q2 financial results show a net loss of $3.932 million and basic and diluted EPS of -$0.04 for the quarter ended June 30, 2026 [S2].
• The company reported narrowing of net loss in Q2 2026 compared to prior periods [N1].
• Liquidity as of June 30, 2026, includes $34.012 million in cash and equivalents, current assets of $38.299 million, and current liabilities of $5.45 million, resulting in a current ratio of 7.03 and a cash ratio of 6.24, indicating strong short-term financial position [S2].
• The company is a smaller reporting company and is not a shell company [S1].
• Shares outstanding as of March 20, 2026, were approximately 89.35 million [S1].
• The company has reiterated risk factors including the need for additional capital, clinical trial risks, regulatory approval uncertainties, and dependence on the success of Zervimesine [S1].